DBMG yields 3.63% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 9
Combined, DBMG + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DBMG + JNJ for your $10,000?
DBM Global Inc., together with its subsidiaries, operates as steel fabrication and erection contractor in Canada, Australia, New Zealand, India, the Philippines, Thailand, the United Kingdom, and the United States. The company offers integrated structural and steel construction services; and professional services, including design-assist/design-build, pre-construction design and budgeting, steel management, fabrication, erection, and 3D building information modeling. It also fabricates trusses and girders; provides fabrication and erection of large-diameter water pipe and water storage tanks; provides integrated solutions for digital engineering, modeling and detailing, construction, and heavy equipment installation, as well as facility services, including maintenance, repair, and installation. In addition, the company manufactures pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators, and various customized products. It provides its services for projects in a range of markets that comprise commercial, industrial, and infrastructure construction projects, such as high- and low-rise buildings and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, metal processing, refineries, pulp and paper mills, and power plants. The company was formerly known as Schuff International, Inc. and changed its name to DBM Global Inc. in September 2016. DBM Global Inc. was incorporated in 2001 and is based in Phoenix, Arizona. DBM Global Inc. is a subsidiary of HC2 Holdings, Inc.
Full DBMG Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.